The Nucleoshuttling of the ATM Protein: A Unified Model to Describe the Individual Response to High- and Low-Dose of Radiation?

ATM DSB repair radiosensitivity

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
28 Jun 2019
Historique:
received: 21 05 2019
revised: 22 06 2019
accepted: 25 06 2019
entrez: 3 7 2019
pubmed: 3 7 2019
medline: 3 7 2019
Statut: epublish

Résumé

The evaluation of radiation-induced (RI) risks is of medical, scientific, and societal interest. However, despite considerable efforts, there is neither consensual mechanistic models nor predictive assays for describing the three major RI effects, namely radiosensitivity, radiosusceptibility, and radiodegeneration. Interestingly, the ataxia telangiectasia mutated (ATM) protein is a major stress response factor involved in the DNA repair and signaling that appears upstream most of pathways involved in the three precited RI effects. The rate of the RI ATM nucleoshuttling (RIANS) was shown to be a good predictor of radiosensitivity. In the frame of the RIANS model, irradiation triggers the monomerization of cytoplasmic ATM dimers, which allows ATM monomers to diffuse in nucleus. The nuclear ATM monomers phosphorylate the H2AX histones, which triggers the recognition of DNA double-strand breaks and their repair. The RIANS model has made it possible to define three subgroups of radiosensitivity and provided a relevant explanation for the radiosensitivity observed in syndromes caused by mutated cytoplasmic proteins. Interestingly, hyper-radiosensitivity to a low dose and adaptive response phenomena may be also explained by the RIANS model. In this review, the relevance of the RIANS model to describe several features of the individual response to radiation was discussed.

Identifiants

pubmed: 31261657
pii: cancers11070905
doi: 10.3390/cancers11070905
pmc: PMC6678722
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Commissariat Général à l'Investissement
ID : INDIRA

Références

C R Acad Sci III. 1999 Feb-Mar;322(2-3):167-75
pubmed: 10196669
Oncogene. 1999 Dec 2;18(51):7334-42
pubmed: 10602489
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):871-6
pubmed: 10639172
Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):379-89
pubmed: 11173131
Br J Cancer. 2001 Apr 6;84(7):892-6
pubmed: 11286467
Nature. 1975 Dec 4;258(5534):427-9
pubmed: 1196376
Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):251-66
pubmed: 12118559
Nature. 2003 Jan 30;421(6922):499-506
pubmed: 12556884
Nat Genet. 2003 Apr;33(4):497-501
pubmed: 12640452
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62
pubmed: 12679524
EMBO J. 2003 Jun 2;22(11):2860-71
pubmed: 12773400
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007
Radiat Res. 2003 Oct;160(4):381-407
pubmed: 12968934
Cancer Res. 2004 Apr 1;64(7):2390-6
pubmed: 15059890
DNA Repair (Amst). 2004 Aug-Sep;3(8-9):1227-35
pubmed: 15279811
Radiother Oncol. 2004 Dec;73(3):373-82
pubmed: 15588885
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):317-9
pubmed: 16168825
Oncogene. 2007 Feb 15;26(7):993-1002
pubmed: 16909103
J Neurochem. 2007 Jan;100(2):337-45
pubmed: 17241156
Int J Radiat Biol. 2007 May;83(5):319-29
pubmed: 17457757
Toxicol Appl Pharmacol. 2007 Jul 1;222(1):122-8
pubmed: 17459441
Int J Radiat Biol. 2008 Feb;84(2):107-25
pubmed: 18246480
Nat Med. 2008 Jul;14(7):767-72
pubmed: 18587406
J Clin Invest. 2009 Jan;119(1):91-8
pubmed: 19075392
Int J Radiat Biol. 2009 Jan;85(1):87-95
pubmed: 19205987
Environ Health Perspect. 1991 Aug;94:135-41
pubmed: 1954924
Int J Radiat Biol. 2009 Jul;85(7):539-73
pubmed: 19557599
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):235-43
pubmed: 19695441
Curr Biol. 2009 Dec 29;19(24):2091-6
pubmed: 19962314
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4153-8
pubmed: 20160076
Mol Cell. 2010 Oct 8;40(1):63-74
pubmed: 20932475
Science. 2010 Oct 22;330(6003):517-21
pubmed: 20966255
Drug Discov Today. 2011 Apr;16(7-8):332-8
pubmed: 21315178
Radiat Res. 2012 Mar;177(3):229-43
pubmed: 22171960
Radiat Res. 2012 Aug;178(2):AV146-72
pubmed: 22870966
Ann ICRP. 2012 Feb;41(1-2):1-322
pubmed: 22925378
Int J Radiat Biol. 2013 Oct;89(10):813-22
pubmed: 23631649
FEBS J. 2013 Jul;280(14):3180-93
pubmed: 23647631
J Theor Biol. 2013 Sep 21;333:135-45
pubmed: 23735818
Mol Neurobiol. 2014 Jun;49(3):1200-11
pubmed: 24277524
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):709-13
pubmed: 24969789
Annu Rev Biochem. 2015;84:711-38
pubmed: 25580527
Radiology. 2015 Feb;274(2):314-8
pubmed: 25625740
PLoS One. 2015 Apr 28;10(4):e0121141
pubmed: 25919483
Med Princ Pract. 2016;25(2):101-9
pubmed: 26571215
J Theor Biol. 2016 Apr 7;394:93-101
pubmed: 26807808
Health Phys. 2016 Mar;110(3):256-9
pubmed: 26808876
Health Phys. 2016 Mar;110(3):276-80
pubmed: 26808882
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):450-60
pubmed: 26867874
Int J Radiat Biol. 2016;92(3):117-31
pubmed: 26907628
Am J Pathol. 2016 Jul;186(7):1750-1753
pubmed: 27219493
Int J Radiat Biol. 2016 Aug;92(8):405-26
pubmed: 27266588
Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):629-36
pubmed: 27681759
Mutat Res. 2016 Oct - Dec;770(Pt B):369-386
pubmed: 27919342
Biochim Biophys Acta Biomembr. 2017 Mar;1859(3):295-300
pubmed: 27989745
Oncotarget. 2017 Jun 13;8(24):38326-38336
pubmed: 28418844
Int J Radiat Biol. 2017 Oct;93(10):1079-1092
pubmed: 28532210
Mol Neurobiol. 2018 Jun;55(6):4973-4983
pubmed: 28786016
Semin Radiat Oncol. 2017 Oct;27(4):310-315
pubmed: 28865513
Eur J Epidemiol. 2017 Dec;32(12):1047-1054
pubmed: 28929329
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):353-360
pubmed: 29353653
Int J Radiat Biol. 2018 May;94(5):503-512
pubmed: 29533136
Mutat Res. 1987 Jul;184(1):29-38
pubmed: 2955220
Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):491-492
pubmed: 29726366
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):690-693
pubmed: 29893278
Crit Rev Oncog. 2018;23(1-2):69-92
pubmed: 29953368
Dose Response. 2018 Aug 06;16(3):1559325818789836
pubmed: 30093841
Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):709-718
pubmed: 30342967
Radiat Res. 1987 Sep;111(3):385-405
pubmed: 3659275
Phys Med Biol. 1973 Jan;18(1):78-87
pubmed: 4803965
Mutat Res. 1983 Feb;112(1):23-32
pubmed: 6828038
Int J Radiat Oncol Biol Phys. 1981 May;7(5):621-9
pubmed: 7275727
Cancer Res. 1980 Mar;40(3):926-32
pubmed: 7471106
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
Radiat Res. 1995 Feb;141(2):160-9
pubmed: 7838954
Cancer Res. 1995 Mar 15;55(6):1232-4
pubmed: 7882314
Int J Radiat Biol. 1993 May;63(5):639-50
pubmed: 8099110
Cancer Res. 1994 May 15;54(10):2544-7
pubmed: 8168076
Radiat Res. 1993 Jan;133(1):41-51
pubmed: 8434112
Mutat Res. 1996 Nov 4;358(2):171-83
pubmed: 8946022
Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10146-51
pubmed: 9707615
Neurosci Lett. 1998 Aug 21;252(3):195-8
pubmed: 9739994

Auteurs

Elise Berthel (E)

Institut National de la Santé et de la Recherche Médicale, UA8, Radiations: Defense, Health and Environment, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.

Nicolas Foray (N)

Institut National de la Santé et de la Recherche Médicale, UA8, Radiations: Defense, Health and Environment, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France. Nicolas.foray@inserm.fr.

Mélanie L Ferlazzo (ML)

Institut National de la Santé et de la Recherche Médicale, UA8, Radiations: Defense, Health and Environment, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon, France.

Classifications MeSH